Research programme: immunotherapies - Selecta Biosciences

Drug Profile

Research programme: immunotherapies - Selecta Biosciences

Latest Information Update: 25 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi
  • Developer Sanofi; Selecta Biosciences
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Coeliac disease; Food hypersensitivity

Most Recent Events

  • 06 Feb 2017 Preclinical trials in Coeliac disease in USA (Parenteral) before February 2017
  • 06 Feb 2017 Pharmacodynamics data from a preclinical study in Food allergy and Celiac disease presented at the GTCbio’s 5th Immunogenicity & Immunotoxicity Conference in San Diego, CA
  • 10 Nov 2016 Selecta Biosciences acquires rights for immunotherapies from Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top